Department of Psychology and Neuroscience, University of North Carolina, Chapel Hill, NC, USA.
Neuroscience Center, University of North Carolina, Chapel Hill, NC, USA.
Neuropsychopharmacology. 2018 May;43(6):1212-1223. doi: 10.1038/npp.2017.244. Epub 2017 Oct 9.
Adaptations in glutamate signaling within the brain's reward circuitry are observed following withdrawal from several abused drugs, including cocaine. These include changes in intrinsic cellular excitability, glutamate release, and glutamate uptake. Pharmacological or optogenetic reversal of these adaptations have been shown to reduce measures of cocaine craving and seeking, raising the hypothesis that regulation of glutamatergic signaling represents a viable target for the treatment of substance use disorders. Here, we tested the hypothesis that administration of the compound riluzole, which regulates glutamate dynamics in several ways, would reduce cocaine seeking in the rat self-administration and reinstatement model of addiction. Riluzole dose-dependently inhibited cue- and cocaine-primed reinstatement to cocaine, but did not affect locomotor activity or reinstatement to sucrose seeking. Moreover, riluzole reversed bidirectional cocaine-induced adaptations in intrinsic excitability of prelimbic (PL) and infralimbic (IL) pyramidal neurons; a cocaine-induced increase in PL excitability was decreased by riluzole, and a cocaine-induced decrease in IL excitability was increased to normal levels. Riluzole also reversed the cocaine-induced suppression of the high-affinity glutamate transporter 1 (EAAT2/GLT-1) in the nucleus accumbens (NAc). GLT-1 is responsible for the majority of glutamate uptake in the brain, and has been previously reported to be downregulated by cocaine. These results demonstrate that riluzole impairs cocaine reinstatement while rectifying several cellular adaptations in glutamatergic signaling within the brain's reward circuitry, and support the hypothesis that regulators of glutamate homeostasis represent viable candidates for pharmacotherapeutic treatment of psychostimulant relapse.
在几种滥用药物(包括可卡因)戒断后,大脑奖励回路中的谷氨酸信号适应会发生变化。这些变化包括细胞内在兴奋性、谷氨酸释放和谷氨酸摄取的改变。已经证明,这些适应的药理学或光遗传逆转可以减少可卡因的渴望和寻求,这提出了一个假设,即调节谷氨酸能信号传递代表了治疗物质使用障碍的可行目标。在这里,我们测试了这样一个假设,即给予化合物利鲁唑可以通过多种方式调节谷氨酸动力学,从而减少大鼠自我给药和成瘾复吸模型中的可卡因寻求。利鲁唑剂量依赖性地抑制了线索和可卡因引发的可卡因复吸,但不影响运动活动或对蔗糖寻求的复吸。此外,利鲁唑逆转了可卡因引起的内侧前额叶皮质(PL)和下边缘皮质(IL)锥体神经元内在兴奋性的双向适应;利鲁唑降低了可卡因引起的 PL 兴奋性增加,而可卡因引起的 IL 兴奋性降低恢复到正常水平。利鲁唑还逆转了可卡因对伏隔核(NAc)中高亲和力谷氨酸转运体 1(EAAT2/GLT-1)的抑制。GLT-1 负责大脑中大部分谷氨酸的摄取,先前有报道称可卡因会使其下调。这些结果表明,利鲁唑在损害可卡因复吸的同时,纠正了大脑奖励回路中谷氨酸能信号传递的几种细胞适应,支持了谷氨酸稳态调节剂代表治疗精神兴奋剂复发的可行药物治疗候选物的假设。